Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration
Veterinary Sciences · 01.05.2026 · 13 (5) · 445
DOI: 10.3390/vetsci13050445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Sciences, online erschienen am 01.05.2026. Verfasst von Naomi C Kirkwood und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BOVA, BOVA Aus.
Abstract (Originalsprache)
Ertugliflozin is a sodium-glucose co-transporter-2 inhibitor that has demonstrated promise as a treatment for hyperinsulinaemia in horses. Despite the frequent use of ertugliflozin in equine clinical practice, the pharmacokinetics of this drug in horses has not been established. The aim of the present study was to determine the pharmacokinetics of one supratherapeutic dose (0.25 mg/kg) of ertugliflozin in eight horses. Horses were defined as being healthy by physical examination, haematological, blood biochemical and oral sugar test (OST) results. Plasma concentrations of ertugliflozin were quantified using high-performance liquid chromatography–tandem mass spectrometry 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 14, 18, 24, 30, 36, 48, 60, 72, 96, and 120 h after drug administration enterally. Non-compartmental analysis led to determination of key pharmacokinetic variables, including mean ± SD time to maximum concentration (Tmax) of 0.91 ± 0.13 h, maximum measured concentration (Cmax) of 267.52 ± 25.37 ng/mL, terminal elimination half-life (T1/2) of 17.65 ± 3.15 h and apparent oral clearance (CL/F) of 106.95 ± 27.53 mL/h/kg. No clinical signs of adverse effects or blood biochemical abnormalities occurred after drug administration. The results of this study suggest that a single supratherapeutic dose of ertugliflozin in healthy horses is safe. The pharmacokinetics of enterally administered ertugliflozin in horses are similar to pharmacokinetics of the drug in humans and the long T1/2 makes ertugliflozin suitable for once daily dosing in horses. It is proposed that a starting dose for ertugliflozin in horses be in the range 0.05–0.1 mg/kg. Further pharmacokinetic studies are required to optimise the dose regimen for treating horses with hyperinsulinaemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Agricultural, Environmental and Veterinary Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia.
- Gulbali Institute, Charles Sturt University, Albert Pugsley Place, Wagga Wagga, NSW 2678, Australia.
- EMT Consulting, Tiverton EX16 9JU, UK.
ORCID-Profile: Naomi C Kirkwood, Kristopher J Hughes, Amy L Lovett, Gregory S Doran, David I Rendle, Scott H Edwards
Förderung
- BOVA
- BOVA Aus
Zitieren
APA
Kirkwood, N. C., Hughes, K. J., Lovett, A. L., Doran, G. S., Rendle, D. I., & Edwards, S. H. (2026). Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration. Veterinary Sciences, 13(5), 445. https://doi.org/10.3390/vetsci13050445
Vancouver
Kirkwood NC, Hughes KJ, Lovett AL, Doran GS, Rendle DI, Edwards SH. Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration. Veterinary Sciences. 2026;13(5):445. doi:10.3390/vetsci13050445
BibTeX
@article{Kirkwood2026,
author = {Kirkwood, Naomi C and Hughes, Kristopher J and Lovett, Amy L and Doran, Gregory S and Rendle, David I and Edwards, Scott H},
title = {Pharmacokinetics of Ertugliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2i) in Horses After Enteral Administration},
journal = {Veterinary Sciences},
year = {2026},
volume = {13},
number = {5},
pages = {445},
doi = {10.3390/vetsci13050445}
}
EUVIMED